Cantor Fitzgerald Thinks Theravance Biopharma’s Stock is Going to Recover

In a report released yesterday, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Theravance Biopharma (TBPH), with a price target of $55. The company’s shares closed yesterday at $22.84, close to its 52-week low of $21.04.

Chen commented:

“. We reiterate our OW rating and $55 PT. 3/26, we hosted meetings with TBPH’s senior management team. In attendance were CEO Rick Winningham, CMO Brett Haumann, and IR Alex Dobbin. In our view, attention is growing for TBPH’s pipeline of organ-selective therapies, with gut- selective pan-JAK TD-1473 being a big focus ahead of data potentially next year (see our recent deep dive here). We think ampreloxetine (or TD-9855) also deserves greater attention, with the five-month Phase 2 data now to be presented in an oral presentation at the upcoming July (see our recent deep dive here).”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 12.9% and a 45.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theravance Biopharma with a $47.50 average price target.

See today’s analyst top recommended stocks >>

Based on Theravance Biopharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $50.19 million. In comparison, last year the company had a GAAP net loss of $86.92 million.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin.